AQST - Latest News
Aquestive Therapeutics, Inc. (AQST), operates in Healthcare / Drug Manufacturers - Specialty & Generic, trades on NASDAQ.
Market capitalization stands near $578.4M. Beta to the broader market is 1.49.
The article list below shows the most recent AQST headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent AQST Headlines
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
globenewswire.com - Oct 15, 2026
WARREN, N. J.
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
prnewswire.com - Oct 7, 2026
SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc.
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
globenewswire.com - Sep 29, 2026
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotech
Aquestive Therapeutics, Inc. $AQST Shares Sold by Squarepoint Ops LLC
defenseworld.net - Sep 24, 2026
Squarepoint Ops LLC reduced its position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) by 71.
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
globenewswire.com - Sep 17, 2026
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026 FDA will determine the resubm
How News Affects AQST Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track AQST's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked AQST news questions
- What is the latest AQST news headline?
- The most recent AQST headline (Oct 15, 2026) is "Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the AQST news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What AQST news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual AQST options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.